December 2025
FDA Delays Decision on Sanofi’s Oral Multiple Sclerosis Drug to December 2025
FDA action date; Sanofi; tolebrutinib; multiple sclerosis; BTK inhibitor; nrSPMS; drug review delay; December 2025; PDUFA
Actionable Insights Powered by AI
FDA action date; Sanofi; tolebrutinib; multiple sclerosis; BTK inhibitor; nrSPMS; drug review delay; December 2025; PDUFA